What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Christopher G. Willett mostly deals with Surgery, Internal medicine, Radiation therapy, Colorectal cancer and Oncology.
His Surgery study incorporates themes from Neoadjuvant therapy, Cancer and Carcinoma.
His Internal medicine study which covers Gastroenterology that intersects with Adjuvant.
His work deals with themes such as Chemotherapy, Adjuvant therapy, Survival rate, Rectum and Randomized controlled trial, which intersect with Radiation therapy.
His research in Colorectal cancer intersects with topics in Bevacizumab and MEDLINE.
His research investigates the connection with Oncology and areas like Disease which intersect with concerns in Perioperative, General surgery, Systemic therapy, Immunology and Antiangiogenic therapy.
His most cited work include:
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (1739 citations)
- Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. (1072 citations)
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 (950 citations)
What are the main themes of his work throughout his whole career to date?
Radiation therapy, Internal medicine, Oncology, Surgery and Colorectal cancer are his primary areas of study.
Christopher G. Willett has included themes like Cancer, Chemotherapy and Rectum in his Radiation therapy study.
Many of his studies on Internal medicine apply to Gastroenterology as well.
Christopher G. Willett usually deals with Oncology and limits it to topics linked to Capecitabine and Oxaliplatin.
The Surgery study combines topics in areas such as Carcinoma and Adenocarcinoma.
Christopher G. Willett works mostly in the field of Colorectal cancer, limiting it down to topics relating to Disease and, in certain cases, General surgery, as a part of the same area of interest.
He most often published in these fields:
- Radiation therapy (41.97%)
- Internal medicine (40.23%)
- Oncology (33.85%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (40.23%)
- Oncology (33.85%)
- Colorectal cancer (27.66%)
In recent papers he was focusing on the following fields of study:
Christopher G. Willett focuses on Internal medicine, Oncology, Colorectal cancer, Radiation therapy and Cancer.
His Internal medicine study typically links adjacent topics like Gastroenterology.
His Oncology research incorporates elements of Gemcitabine, Locally advanced, Chemotherapy, Randomized controlled trial and Esophageal cancer.
His studies deal with areas such as Neoadjuvant therapy, Combined Modality Therapy, Disease and General surgery as well as Colorectal cancer.
He combines subjects such as Clinical trial and Rectal Adenocarcinoma with his study of Radiation therapy.
His Cancer research includes elements of Proportional hazards model and Lymph node, Pathology.
Between 2012 and 2021, his most popular works were:
- Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology (768 citations)
- Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology (394 citations)
- RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. (349 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Internal medicine, Oncology, Colorectal cancer, Disease and Radiation therapy.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Bioinformatics.
His work carried out in the field of Oncology brings together such families of science as Cancer, Esophageal cancer, Adenocarcinoma and Chemotherapy.
He interconnects Neoadjuvant therapy and General surgery in the investigation of issues within Colorectal cancer.
His Disease research includes themes of Combined Modality Therapy, Perioperative, Systemic therapy and MEDLINE.
His specific area of interest is Radiation therapy, where Christopher G. Willett studies Chemoradiotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
